{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:00:45Z","timestamp":1776693645213,"version":"3.51.2"},"reference-count":56,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The advent of novel small-molecule inhibitors has transformed the treatment approaches for patients with chronic lymphocytic leukemia (CLL). These therapies are becoming increasingly used in patients with relapsed disease, patients with 17p deletion, and, as of recently, also in the frontline setting for previously untreated patients with CLL. Moreover, many of these are oral therapies that are significantly less myelosuppressive than chemoimmunotherapy. However, these agents have their own set of unique toxicities with which providers must gain familiarity. There is also ongoing development of second-generation agents which have the promise of less toxicity than the US Food and Drug Administration (FDA)\u2013approved compounds. In addition, immunotherapy and the role of the microenvironment are becoming increasingly important and have therapeutic implications in the treatment of patients with CLL. Ultimately, investigators need to evaluate how to position these and other new exciting therapies and decide on the ultimate role for chemoimmunotherapy in modern times.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.137","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T11:05:27Z","timestamp":1480676727000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Novel agents in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"2016","author":[{"given":"Nicole","family":"Lamanna","sequence":"first","affiliation":[{"name":"Leukemia Service, Chronic Lymphocytic Leukemia Program, Hematologic Malignancies Section, Herbert Irving Comprehensive Cancer Center, New York\u2013Presbyterian\/Columbia University Medical Center, New York, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, Sue and Ralph Stern Center for Clinical Trials & Research, Division of Hematology\/Oncology, Department of Medicine, University of California, Irvine, Orange, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"16","key":"2019111703392480000_B1","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"16","key":"2019111703392480000_B2","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111703392480000_B3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111703392480000_B4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","article-title":"BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-\u03baB","volume":"25","author":"Rushworth","year":"2013","journal-title":"Cell Signal"},{"issue":"29","key":"2019111703392480000_B5","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111703392480000_B6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111703392480000_B7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111703392480000_B8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","author":"O\u2019Brien","journal-title":"Lancet Oncol"},{"key":"2019111703392480000_B9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111703392480000_B10","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703392480000_B11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111703392480000_B12","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111703392480000_B13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"2019111703392480000_B14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111703392480000_B15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111703392480000_B16","volume-title":"Blood","author":"Tam","year":"2015"},{"key":"2019111703392480000_B17","author":"Fegan","year":"2014"},{"issue":"4","key":"2019111703392480000_B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2019111703392480000_B19","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111703392480000_B20","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111703392480000_B21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111703392480000_B22","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"issue":"2","key":"2019111703392480000_B23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2019111703392480000_B24","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111703392480000_B25","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"suppl","key":"2019111703392480000_B26","article-title":"Update on a phase I study of the selective PI3K\u03b4 idelalisib (GS-1101) in combination with rituximab and\/or bendamustine in patients with relapsed or refractory CLL","volume":"31","author":"Barrientos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111703392480000_B27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111703392480000_B28","volume-title":"Blood","author":"Zelenetz","year":"2015"},{"key":"2019111703392480000_B29","article-title":"Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-\u03b4,\u03b3, in patients with chronic lymphocytic leukemia [abstract]","volume-title":"Blood","author":"Flinn","year":"2013"},{"key":"2019111703392480000_B30","article-title":"TGR-1202, a novel once daily PI3K-delta inhibitor, demonstrates clinical activity with a favorable safety profile in patients with CLL and B-cell lymphoma [abstract]","volume-title":"Blood","author":"O\u2019Connor","year":"2015"},{"issue":"5","key":"2019111703392480000_B31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111703392480000_B32","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111703392480000_B33","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111703392480000_B34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2019111703392480000_B35","article-title":"Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) [abstract]","volume-title":"Blood","author":"Sharman","year":"2013"},{"key":"2019111703392480000_B36","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","author":"Barr","journal-title":"Blood"},{"issue":"2","key":"2019111703392480000_B37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"issue":"2","key":"2019111703392480000_B38","first-page":"F151","article-title":"The role of the bcl-2\/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy","volume":"1333","author":"Strasser","year":"1997","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2019111703392480000_B39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/bcmd.2000.0372","article-title":"Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo","volume":"27","author":"Schmitt","year":"2001","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2019111703392480000_B40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/ard.1994.4.71","article-title":"Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression","volume":"4","author":"Kitada","year":"1994","journal-title":"Antisense Res Dev"},{"issue":"5","key":"2019111703392480000_B41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703392480000_B42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111703392480000_B43","article-title":"Deep and durable responses following venetoclax (ABT-199\/GDC-0199) combined with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia: results from a phase 1b study [abstract]","volume-title":"Blood","author":"Ma","year":"2015"},{"key":"2019111703392480000_B44","article-title":"Results of the Safety Run-In Phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase-III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC-0199\/ABT-199) with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions [abstract]","volume-title":"Blood","author":"Fischer","year":"2015"},{"key":"2019111703392480000_B45","article-title":"Safety and efficacy from a combination of venetoclax (GDC-0199\/ABT-199) and obinutuzumab in patients with relapsed\/refractory or previously untreated chronic lymphocytic leukemia: results from an ongoing phase Ib study (GP28331) [abstract]","volume-title":"Blood","author":"Flinn","year":"2015"},{"key":"2019111703392480000_B46","article-title":"Preliminary results of a phase 2, open-label study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy [abstract]","volume-title":"Blood","author":"Jones","year":"2015"},{"key":"2019111703392480000_B47","article-title":"Venetoclax (ABT-199\/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed\/refractory chronic lymphocytic leukemia with 17p deletion: results of the Pivotal International Phase 2 Study [abstract]","volume-title":"Blood","author":"Stilgenbauer","year":"2015"},{"issue":"12","key":"2019111703392480000_B48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"9980","key":"2019111703392480000_B49","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"2019111703392480000_B50","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"177","key":"2019111703392480000_B51","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"21","key":"2019111703392480000_B52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.873.873","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells against CD19 (CTL019) in patients with relapsed refractory CLL","volume":"122","author":"Porter","year":"2013","journal-title":"Blood"},{"key":"2019111703392480000_B53","article-title":"PD-1 blockade with pembrolizumab (MK-3475) in relapsed\/refractory CLL including Richter transformation: an early efficacy report from a phase 2 trial (MC1485) [abstract]","volume-title":"Blood","author":"Ding","year":"2015"},{"issue":"7","key":"2019111703392480000_B54","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/leu.2014.32","article-title":"The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model","volume":"28","author":"Beckwith","year":"2014","journal-title":"Leukemia"},{"issue":"36","key":"2019111703392480000_B55","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703392480000_B56","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/137\/1250582\/hem088361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/137\/1250582\/hem088361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:39:47Z","timestamp":1573961987000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/137\/21043\/Novel-agents-in-chronic-lymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.137","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}